MREO

Mereo is a clinical-stage biopharma, so the headline valuation ratios are noise: a P/S of 534x against $500K of milestone-type revenue tells you nothing, and the -8,376% net margin and -102% ROE are simply what a pre-commercial drug developer looks like. The real asset is the pipeline — above all setrusumab for osteogenesis imperfecta, partnered with (and funded/commercialized by) Ultragenyx, with Mereo retaining European/UK commercialization rights per the 10-K. Secondary shots are alvelestat in AATD and a stack of out-licensed/partnered programs (vantictumab in ADO2, navicixizumab, leflutrozole). This is a call on a binary clinical/regulatory outcome, not on financial trends.

The balance sheet is the strongest part of the story: $41.0M cash against just $5.0M total liabilities (liabilities/equity 0.12x), no meaningful debt, and $40.9M of equity. Losses are contained and stable — operating loss of $40.1M improved 15.3% YoY, net loss $41.9M, and operating cash burn of $31.0M actually improved 5.7%. Capex is negligible ($20K). Management explicitly guides that existing cash funds committed trials and operations 'into mid-2027' — roughly a year of runway from the latest filing.